CagriSema vs Tesofensine
Compare the research profiles of CagriSema and Tesofensine. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesCagriSema
CagriSema (Semaglutide + Cagrilintide)
Category
weight-loss
Research Level
Phase 3 Clinical Trials
FDA Status
clinical-trials
Tesofensine
Tesofensine
Category
weight-loss
Research Level
Phase 3 Clinical Trials
FDA Status
clinical-trials
Detailed Comparison
| Aspect | CagriSema | Tesofensine |
|---|---|---|
| Overview | A next-generation combination therapy by Novo Nordisk combining semaglutide with cagrilintide (an amylin analogue). Aims for even stronger weight loss effects than Wegovy alone.... | A triple monoamine reuptake inhibitor rising fast in popularity for its potent appetite suppression capabilities. Originally developed for Parkinson's and Alzheimer's, now being studied for obesity.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Dual mechanism: semaglutide activates GLP-1 receptors while cagrilintide mimics amylin, a hormone that slows gastric emptying and promotes satiety. Th... | Inhibits reuptake of norepinephrine, dopamine, and serotonin, leading to reduced appetite and increased energy expenditure. Works on brain chemistry r... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.